{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:35:44Z","timestamp":1791318944917,"version":"4.3.1"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,10,23]],"date-time":"2004-10-23T00:00:00Z","timestamp":1098489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The prognosis for children with recurrent\/refractory sarcomas is poor. We determined the overall response rate (ORR) and overall survival (OS) of children with recurrent\/refractory sarcomas who were given ifosfamide, carboplatin, and etoposide (ICE) in three Children's Cancer Group (CCG) phase I\/II trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Children with recurrent\/refractory sarcoma were treated with ifosfamide (1,800 mg\/m<jats:sup>2<\/jats:sup>\/day on day 0\u20134), carboplatin (400 mg\/m<jats:sup>2<\/jats:sup>\/day on day 0\u20131), etoposide (100 mg\/m<jats:sup>2<\/jats:sup>\/day on day 0\u20134) and either rhG\u2010CSF (10 \u03bcg\/kg\/day vs. 5 \u03bcg\/kg\/day, CCG\u20100894, 71 patients), PIXY321 (500\u20131,000 \u03bcg\/m<jats:sup>2<\/jats:sup>\/day, CCG\u20100924, 14 patients), or rhG\u2010CSF (5 \u03bcg\/kg\/day) and IL\u20106 (2.5\u20135 \u03bcg\/kg\/day, CCG\u20100931, 12 patients).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety\u2010seven patients were evaluable for tumor response, 56 male and 41 female, median age 14.1 years (range 2.8\u201322.5 years). Tumor types were osteosarcoma (OTS) (n\u2009=\u200934), rhabdomyosarcoma (n\u2009=\u200927), Ewing sarcoma (EWS) (n\u2009=\u200921), soft tissue sarcoma\u2010not otherwise specified (n\u2009=\u20095), undifferentiated sarcoma (n\u2009=\u20096), fibrosarcoma (n\u2009=\u20092), peripheral primitive neuroectodermal tumor (n\u2009=\u20091), and extraosseous Ewing (n\u2009=\u20091). The ORR was 51% (27% complete response [CR]). OS at 1 and 2 years was 49% and 28%, respectively. Patients with CR or partial response (PR) had significantly increased 1\u2010 and 2\u2010year OS, 71% and 41%, respectively, (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Rhabdomyosarcoma patients with embryonal histology had significant improvement in 1\u2010 and 2\u2010year OS: 82% and 46%, respectively, compared with other histologies, (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.005).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The ORR to ICE reinduction chemotherapy in children with recurrent\/refractory sarcoma was 51%. OS of 1 and 2 years appeared significantly improved in patients who had CR or PR following ICE reinduction therapy or who had rhabdomyosarcoma with embryonal histology. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20227","type":"journal-article","created":{"date-parts":[[2004,11,12]],"date-time":"2004-11-12T20:48:24Z","timestamp":1100292504000},"page":"338-347","source":"Crossref","is-referenced-by-count":110,"title":["Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent\/refractory sarcoma: The Children's Cancer Group (CCG) experience"],"prefix":"10.1002","volume":"44","author":[{"given":"Patrick","family":"Van Winkle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying\u2010Kuen","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Reaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3487"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3697"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.9.1849"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907293410507"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.081"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3108"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200101000-00008"},{"key":"e_1_2_6_9_2","first-page":"35","article-title":"Clinical trials with ifosfamide: The Indiana University experience","volume":"19","author":"Loehrer P","year":"1992","journal-title":"Semin Oncol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(85)90015-5"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(85)90014-3"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198503143121106"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00224-X"},{"key":"e_1_2_6_14_2","first-page":"297","article-title":"Effects if carboplatin combination with etoposide against leukemia\/lymphoma cell lines","volume":"23","author":"Akutsu M","year":"1996","journal-title":"Gan To Kagaky Ryoho"},{"key":"e_1_2_6_15_2","first-page":"2075","article-title":"Distinctive potentiating effects of cisplatin and\/or ifosfamide combined with etoposide in human small cell lung carcinoma exenografts","volume":"6","author":"Nemati F","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004320000223"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00253234"},{"key":"e_1_2_6_18_2","first-page":"1755","article-title":"Phase II study of VP\u201016\u2010213 in childhood malignant disease: A Children's Cancer Group report","volume":"63","author":"Chard RJ","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901215)66:12<2465::AID-CNCR2820661204>3.0.CO;2-N"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940215)73:4<1297::AID-CNCR2820730427>3.0.CO;2-#"},{"key":"e_1_2_6_21_2","first-page":"115","article-title":"High\u2010dose ifosfamide in advanced osteosarcoma","volume":"69","author":"Marti C","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00263897"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00647446"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950240205"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.5.793"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.249"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950220409"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00170776"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1478"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.8.1191"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.10.1592"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981001)83:7<1449::AID-CNCR24>3.0.CO;2-3"},{"key":"e_1_2_6_34_2","first-page":"58","article-title":"A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte\u2010colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent\/refractory solid tumors: Enhanced hematological responses but a high incidence of grade III\/IV constitutional toxicities","volume":"7","author":"Bracho F","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3115-3"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.426"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00439-X"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199805)30:5<269::AID-MPO2>3.0.CO;2-D"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.554"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199508000-00009"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf028"},{"key":"e_1_2_6_43_2","first-page":"2151","article-title":"Ifosfamide, carboplatin and etoposide (ICE) is an excellent retrieval regimen in children with recurrent\/refractory CNS malignancies: The Children's Cancer Group (CCG) experience","volume":"18","author":"Shen V","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.574"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.12.3091"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.20.4058"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20227","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T01:20:07Z","timestamp":1696900807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,23]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1002\/pbc.20227"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20227","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,23]]}}}